In last trading session, Standard BioTools Inc (NASDAQ:LAB) saw 1.58 million shares changing hands with its beta currently measuring 1.58. Company’s recent per share price level of $1.90 trading at $0.07 or 3.83% at ring of the bell on the day assigns it a market valuation of $705.18M. That closing price of LAB’s stock is at a discount of -60.0% from its 52-week high price of $3.04 and is indicating a premium of 36.32% from its 52-week low price of $1.21. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.69 million shares which gives us an average trading volume of 3.11 million if we extend that period to 3-months.

For Standard BioTools Inc (LAB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.

Standard BioTools Inc (NASDAQ:LAB) trade information

Upright in the green during last session for gaining 3.83%, in the last five days LAB remained trading in the red while hitting it’s week-highest on Friday, 09/20/24 when the stock touched $1.90 price level, adding 8.65% to its value on the day. Standard BioTools Inc’s shares saw a change of -14.03% in year-to-date performance and have moved -9.95% in past 5-day. Standard BioTools Inc (NASDAQ:LAB) showed a performance of -12.84% in past 30-days. Number of shares sold short was 22.25 million shares which calculate 10.19 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 3.25 to the stock, which implies a rise of 41.54% to its current value. Analysts have been projecting 3.25 as a low price target for the stock while placing it at a high target of 3.25. It follows that stock’s current price would drop -71.05% in reaching the projected high whereas dropping to the targeted low would mean a loss of -71.05% for stock’s current value.

Standard BioTools Inc (LAB) estimates and forecasts

Statistics highlight that Standard BioTools Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -29.37% of value to its shares in past 6 months, showing an annual growth rate of 26.83% while that of industry is 22.30. Apart from that, the company came raising its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 8.72% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 56.74% while estimates for its earnings growth in next 5 years are of -8.06%.

Standard BioTools Inc (NASDAQ:LAB)’s Major holders

Insiders are in possession of 1.95% of company’s total shares while institution are holding 72.77 percent of that, with stock having share float percentage of 74.21%. Investors also watch the number of corporate investors in a company very closely, which is 72.77% institutions for Standard BioTools Inc that are currently holding shares of the company. CASDIN CAPITAL, LLC is the top institutional holder at LAB for having 63.96 million shares of worth $113.21 million. And as of 2024-06-30, it was holding 17.1782 of the company’s outstanding shares.

The second largest institutional holder is VIKING GLOBAL INVESTORS LP, which was holding about 58.65 million shares on 2024-06-30. The number of shares represents firm’s hold over 15.7524 of outstanding shares, having a total worth of $103.81 million.